Conclusions
Long-term data from
EORTC 26951
and
RTOG 9402
suggest RT + PCV as standard of care for patients with
anaplastic glioma and 1p/19q co-deletion
NOA-04
data do not support an attempt to achieve
comparable outcomes with monochemotherapy in patients
with 1p/19q co-deleted tumors
RTOG 9802
long-term data suggest a benefit from RT/PCV
compared to RT alone in the entire cohort of grade II tumors
PFS and OS gain in the RTOG 9802 dataset is most
prominent in patients with oligodendroglial (=
1p/19q co-
deleted
?) tumors
Whether
PCV
can be replaced by
temozolomide
remains
unclear